Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients With Large B-Cell Lymphoma Treated with Axicabtagene Ciloleucel

Patient and disease factors present prior to chimeric antigen receptor (CAR) T-cell infusion influence the development of immune-mediated toxicities. In this study, the authors identify an association between a proinflammatory tumor microenvironment and severe cytokine release syndrome and neurotoxicity in patients with large B-cell lymphoma treated with a standard-of-care CAR T-cell product.